Abstract 133P
Background
The aim of this study was to compare the treatment failure patterns after laparoscopic (LG) and open gastrectomy (OG) in locally advanced gastric cancer (LAGC).
Methods
A total of 1792 LAGC patients who underwent radical resection between January 2010 and December 2016 were divided into an LG group (n=1557) and OG group (n=235). Propensity score matching was performed to balance the two groups. Dynamic hazard rates of failure were calculated using the hazard function.
Results
A total of 1175 LAGC patients were included after matching (LG group, n=940; OG, n=235). The treatment failure rate of the whole group was 43.23% (508/1175), accounting for 41.38% (389/940) and 50.64% (119/235) in the LG and OG groups, respectively. The static treatment failure pattern showed that only distant recurrence rate of the LG group was significantly lower than that of the OG group (22.02% vs. 28.94%, P=0.025). Landmark analysis showed a lower early treatment failure rate of the LG group in stage Ib-IIIb subgroup (P=0.004). Furthermore, dynamic hazard curve peaked at 9.4 months (Peak rate=0.0186) and then gradually declined. For stage Ⅰb to Ⅲb patients, time of peak failure hazard was 5.2 months earlier in the OG group (OG versus LG: 11.0 versus 16.2 months). Finally, LG was an independent protective factor associated with early treatment failure in stage Ib-IIIb patients (hazard ratio, 0.63; 95% CI, 0.43-0.93; P=0.019).
Conclusions
Given the differences in treatment failure patterns between LG and OG, shorter-interval surveillance for the first 2 years should be considered for stage Ib-IIIb patients after OG.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session